Why is there a shortage of Xerava (eravacycline)?
Xerava shortages typically happen when supply is constrained at the manufacturer level, distribution disruptions occur, or demand rises faster than production can keep up. When those conditions last long enough, wholesalers and hospitals can see intermittent or delayed fulfillment, especially for certain dosing schedules and inpatient formularies.
What does a Xerava shortage mean for patients and hospitals?
Hospitals facing a Xerava shortage may adjust prescribing by:
- switching to an available alternative antibiotic regimen based on the indication (for example, intra-abdominal infections)
- using smaller quantities per dose schedule where clinically appropriate
- prioritizing patients at highest risk or where the alternative options are less suitable
- relying on pharmacy protocols to ration limited stock while maintaining safety and antimicrobial stewardship
If you’re a patient, ask whether your treatment can be completed with an alternative regimen or whether pharmacy can source Xerava from another supplier or site.
What alternatives are used when Xerava is unavailable?
When Xerava can’t be obtained, clinicians usually move to a guideline- and susceptibility-based alternative for the same infection type. The specific substitute depends on local antibiograms, kidney/liver function, allergy history, and whether cultures show resistance patterns. Common alternatives for severe intra-abdominal infections in practice may include other broad-spectrum agents or combination regimens, but the right choice depends on the patient and hospital formulary.
How long do drug shortages usually last?
The timeline varies by cause. Shortages can resolve quickly if production ramps up or shipments normalize, but some persist for months when there are sustained manufacturing issues or backlogs. Hospitals often tighten inventory controls early in a shortage and then loosen them as allocations improve.
How can families and clinicians check the status of a Xerava shortage?
Practical ways to confirm current availability include:
- asking the hospital pharmacy or infectious diseases service for the latest allocation status
- checking with the buying group or distributor used by the facility
- contacting the prescribing team’s pharmacy liaison (many hospitals track incoming supply by day/week)
What risks should clinicians watch for during a shortage?
During supply constraints, the main risks are:
- delays to starting appropriate therapy
- switching to an alternative agent that may be less optimal for the patient
- broader-than-needed spectrum use, which can worsen resistance pressure
- dosing errors if a substitute is used under time pressure
Hospitals typically mitigate these with protocolized substitution pathways and stewardship oversight.
Who can answer questions if my facility can’t get Xerava?
Your best point of contact is usually:
- the inpatient pharmacist (for sourcing/allocation)
- the antimicrobial stewardship team (for approved substitutions)
- the infectious diseases clinician (for regimen selection based on the indication)
If you tell me where you are located (country/state) and what indication you’re asking about (for example, intra-abdominal infection), I can narrow down what substitution pathways hospitals commonly use and what to ask your pharmacy.